索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]顾颖,李攀,杨雅薇,等.替格瑞洛在急性冠脉综合征治疗中的应用进展[J].国际心血管病杂志,2016,04:200-203.
点击复制

替格瑞洛在急性冠脉综合征治疗中的应用进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年04期
页码:
200-203
栏目:
综述
出版日期:
2016-07-20

文章信息/Info

Title:
-
作者:
顾颖; 李攀; 杨雅薇; 马丽萍
200433 上海,第二军医大学附属长海医院心内科
Author(s):
-
关键词:
急性冠脉综合征; 替格瑞洛; P2Y12受体拮抗剂
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.04.003
文献标识码:
-
摘要:
替格瑞洛是一种新型、可逆的P2Y12受体拮抗剂,其起效快、作用强,停药后血小板功能可迅速恢复。它对血小板聚集的抑制作用个体差异小,不受基因多态性等影响,对氯吡格雷低反应的患者仍有较强的抑制血小板聚集的功能,能明显降低心血管血栓发生率,且出血风险无明显增加,具有良好的有效性和安全性。该文主要介绍替格瑞洛的药动学、药效学、安全性及临床应用中存在的问题。
Abstract:
-

参考文献/References

[1] Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin [J]. Eur Heart J, 2006, 27(9): 1038-1047.
[2] Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study [J]. Circulation, 2009, 120(25): 2577-2585.
[3] Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study [J]. Circulation, 2010, 121(10): 1188-1199.
[4] Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study [J]. J Am Coll Cardiol, 2012, 60(3): 193-199.
[5] Li P, Yang Y, Chen T, et al. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial [J].Sci Rep, 2015, 5:13789.
[6] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes [J]. N Engl J Med, 2009, 361(11): 1045-1057.
[7] Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial [J]. Eur Heart J, 2014, 35(31): 2083-2093.
[8] Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial [J]. Circulation, 2013, 128(10): 1055-1065.
[9] Bellemain-Appaix A, O'Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis [J]. JAMA, 2012, 308(23): 2507-2516.
[10] Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial [J]. Clin res cardiol, 2012, 101(4): 305-312.
[11] Montalescot G, van't Hof AW,Lapostolle F,et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction [J]. N Engl JMed, 2014, 371(11): 1016-1027.
[12] Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes(PLATO)trial [J]. Eur Heart J, 2011, 32(23): 2933-2944.
[13] Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1 [J]. J Cardiovasc Pharma, 2014, 19(2): 209-219.
[14] Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes [J]. Eur Heart J, 2011, 32(23): 2945-2953.
[15] Butler K, Maya J, Teng R. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients [J]. Curr Med Res Opin, 2013, 29(5): 569-577.
[16] Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO(Platelet Inhibition and Patient Outcomes)trial: results of the continuous electrocardiographic assessment substudy [J]. J Am Coll Cardiol, 2011, 57(19): 1908-1916.
[17] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions [J]. J Am Coll Cardiol, 2011, 58(24): e44-122.
[18] Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines [J]. Circulation, 2014, 130(25): e344-426.
[19] Roffi M, Patrono C, Collet JP,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2016,37(3):267-315.
[20] Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction [J]. N Engl J Med, 2015, 372(19):1791-1800.
[21] Goto S, Huang CH, Park SJ, et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome-randomized, double-blind, phase Ⅲ PHILO study [J]. Circ J, 2015, 79(11): 2452-2460.
[22] Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding [J]. J Am Coll Cardiol, 2013, 62(24): 2261-2273.
[23] Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes(PLATO)Trial [J]. Am Heart J, 2015, 169(6): 899-905 e1.
[24] Guo LZ, Kim MH, Jin CD, et al. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects [J]. Platelets, 2015, 26(6): 563-569.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金面上项目(81170223/H0212) 作者单位:200433 上海,第二军医大学附属长海医院心内科 通信作者:马丽萍,Email:lipingma@smmu.edu.cn
更新日期/Last Update: 2016-07-20